Annual Meeting2014: A Phase I Trial Of SAR650984, a CD38 Monoclonal Antibody In Relapsed Or Refractory Multiple Myeloma

Thomas G. Martin, MD
University of California SF
San Francisco, California, USA

A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma

SAR650984 (SAR) is a naked humanized IgG1 monoclonal antibody that binds to the CD38 receptor. SAR kills tumor cells via ADCC, CDC, direct apoptosis without secondary crosslinking and allosteric inhibition on CD38 enzymatic activity. Data on relapsed /refractory multiple myeloma (RRMM) patients (pts) in the dose escalation phase of the study are reported. (NCT01084252).

Visit our website at: http://www.myeloma.org